Related Experiment Video

Updated: Jun 19, 2026

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation

Takafumi Toyohara1, Takehiro Suzuki, Ryo Morimoto

  • 1Division of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Graduate School of Biomedical Engineering, Sendai, Japan.

Journal of the American Society of Nephrology : JASN
|October 31, 2009
PubMed

Insights

Overexpressing kidney transporter SLCO4C1 in renal failure reduced hypertension and uremic toxins. Statins, like pravastatin, may upregulate SLCO4C1, offering potential therapies for chronic kidney disease patients.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Hypertension in chronic kidney disease (CKD) patients is linked to cardiovascular events.
  • Reducing uremic toxins may prevent hypertension and kidney damage progression in CKD.
  • No current therapies effectively reduce uremic toxin accumulation.

Purpose of the Study:

  • To investigate the role of kidney-specific organic anion transporter SLCO4C1 in hypertension and uremic toxin levels in renal failure.
  • To explore the therapeutic potential of upregulating SLCO4C1 in CKD.

Main Methods:

  • Overexpression of human SLCO4C1 in rat kidneys with renal failure.
  • Measurement of blood pressure, cardiac hypertrophy, inflammation markers, and plasma uremic toxin levels.
  • Analysis of SLCO4C1 transcriptional regulation by xenobiotic responsive elements and statins.

Main Results:

  • SLCO4C1 overexpression reduced hypertension, cardiomegaly, and inflammation in renal failure.
  • Overexpression decreased plasma levels of guanidino succinate, asymmetric dimethylarginine, and trans-aconitate.
  • Statins, particularly pravastatin, upregulated SLCO4C1 and enhanced clearance of specific uremic toxins.

Conclusions:

  • SLCO4C1 plays a protective role against hypertension and uremic toxin accumulation in CKD.
  • Upregulating SLCO4C1, potentially through statin therapy, shows therapeutic promise for CKD patients.
  • Targeting SLCO4C1 could offer a novel strategy for managing hypertension and cardiovascular risk in CKD.

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...
Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...